Nordic Capital, a Stockholm, Sweden-based private equity investor, acquired a majority share in IntegriChain, a Philadelphia, PA-based provider of pharmaceutical technology, data, consulting, and outsourcing solutions.
Nordic Capital is acquiring the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016. The terms of the transaction – whose completion is expected before year end and is subject to customary closing conditions, including relevant regulatory approvals – were not disclosed.
The company intends to use the funds to accelerate its growth targets and consolidate its status as a platform for pharma manufacturers to bring their science to market.
Led by Josh Halpern, IntegriChain helps pharma manufacturers bring their science to market, via a data-driven commercialization platform managing all the stages, from strategy to operational execution. The integrated ICyte Platform helps connect the commercial, financial, and operational dimensions of drug access and profitability. ICyte enables pharmaceutical innovators to achieve commercial outcomes by digitalizing daily and recurring business activities and integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net.
IntegriChain currently supports more than 400 pharmaceutical customers with offices in Ambler, PA, and Pune, India.
FinSMEs
09/11/2023